Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. (Q34270375)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22527245%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

Targeted immunotherapy of cancer with CAR T cells: achievements and challenges (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22527245%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22527245%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Grazyna Lipowska-Bhalla

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22527245%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Robert E Hawkins

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22527245%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Dominic G Rothwell

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22527245%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

22 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22527245%20AND%20SRC:MED&resulttype=core&format=json

Cancer Immunology, Immunotherapy

29 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22527245%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22527245%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22527245%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

953-962

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22527245%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00262-012-1254-0

29 January 2020

exact match

0 references

cites work

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Natural history of HLA expression during tumour development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Supernatural T cells: genetic modification of T cells for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Gene modification strategies to induce tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Adoptive T cell therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Building better chimeric antigen receptors for adoptive T cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Impact of chimeric immune receptor extracellular protein domains on T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Graft-versus-leukemia effects of transplantation and donor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Targeting tumours with genetically enhanced T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Integrase-defective lentiviral vectors: progress and applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Treatment of advanced leukemia in mice with mRNA engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Synthetic messenger RNA as a tool for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Immunobiology of allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1254-0

10.1007/S00262-012-1254-0

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22527245%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

29 January 2020

1007877133

0 references

Fatcat ID

release_zvpm646m7jevlcdi7xopv26izq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zvpm646m7jevlcdi7xopv26izq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference